267 results about "Treatment blood" patented technology

A non-invasive method and system for using ultrasound energy for the treatment of conditions resulting from vascular disorders is provided. In one embodiment, an image-treatment approach can be used to locate the blood vessel to be treated and then to ablate it non-invasively, while also monitoring the progress of the treatment. In another embodiment, a transducer is configured to deliver ultrasound energy to the regions of the superficial tissue (e.g., skin) such that the energy is deposited at the particular depth at which the vascular malformations (such as but not limited to varicose veins) are located below the skin surface. The ultrasound transducer can be driven at a number of different frequency regimes such that the depth and shape of energy concentration can match the region of treatment.

A method of treating hemodynamic disfunction by simultaneously pacing both ventricles of a heart. At least one ECG amplifier is arranged to separately detect contraction of each ventricle and a stimulator is then activated for issuing stimulating pulses to both ventricles in a manner to assure simultaneous contraction of both ventricles, thereby to assure hemodynamic efficiency. A first ventricle is stimulated simultaneously with contraction of a second ventricle when the first fails to properly contract. Further, both ventricles are stimulated after lapse of a predetermined A-V escape interval. One of a pair of electrodes, connected in series, is placed through the superior vena cava into the right ventricle and a second is placed in the coronary sinus about the left ventricle. Each electrode performs both pacing and sensing functions. The pacer is particularly suitable for treating bundle branch blocks or slow conduction in a portion of the ventricles.

Kits for use in the treatment of vascular calcified lesions are provided. The subject kits include at least one of: (a) a fluid delivery means for conveying fluid to and from a vascular site; and (b) a dissolution fluid for at least partially dissolving the target lesion. In many embodiments, the kits include both of these components. The subject kits further include instructions for treating vascular calcified lesions with the contents of the kit, where the instructions are typically recorded on a recording medium, e.g. printed on a substrate, such as paper.

Apparatus for treating an aneurysm in a vessel that isolates a volume around the aneurysm, evacuates that volume and heats the aneurysmal wall. A catheter includes one or more inflatable balloons for defining the isolated volume and occluding and preventing any blood flow through the volume. Suction applied through the catheter to the isolated volume withdraws any blood in the isolated volume and displaces the tissue for contact with a thermal source that heats the aneurysmal wall. When the treatment is completed, the balloons are deflated and the catheter is removed from the vessel.

The present invention relates to hexabasic amino amidate derivatives, their preparation process, medicines using them as active components and method for curing diseases of angiogenesis and high vascular osmolarity by using them, and also relates to the application of them as medicines.

A method and apparatus for the treatment of thrombosis, venous insufficiency, and the like, and in particular to an Automated Compulsory Blood Extraction System (ACBES) configured to provide an efficient and safe means for the measured extraction of blood utilizing a device providing, in effect, an artificial leech, but without the infection, control, care, and other limitations associated with the medicinal leech. The preferred embodiment of the present invention utilizes recent micro technological advances to provide a micro mechanical device which mimics and improves upon the bloodletting properties of the medicinal leech utilizing a micro mechanical valve, micropump, and micro sensor arraignment cooperating with a tertiary jaw array having teeth situated thereon. The preferred embodiment of the present invention contemplates an extraction device which may have a head size of one centimeter or less, and which may be utilized in number about the affected area of the patient to provide controlled, precision, pulsed blood extraction via vacuum induction, supplying a controlled dosage of anticoagulant, histamine anesthetic, or the like. Alternative embodiments of the present invention include an independent, single needle, stationary design configured primarily for emergency use, a multi-needle piston design, a large extraction area array design including concentric needles of adjustable depth, and a deep extraction needle design.

Nitrate derivatives of cilostazol are described. They have superior properties and clinical advantages compared to cilostazol in the treatment of vascular and metabolic diseases.

Methods for treating a vascular disease by delivering therapeutic compositions with enhanced endothelium targeting are disclosed.

Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter deliver.

The present invention discloses the use of inhibitors and / or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).

Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

The invention discloses a compound with a general formula (1) disclosed as follow, or salt thereof, or a stereo isomer thereof and a preparation method as well as a medicinal composition which at least comprises at least one compound with the general formula (1), or salt thereof, or a stereo isomer thereof as an active component. The definitions of R1, R2 and R3 are disclosed in the specification. The compound has the function of suppressing platelet coagulation and is used for preventing and treating thrombus or embolism class diseases.

The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

The invention relates to a medicament containing a standardized dry extract of horse chestnut seeds which is active against various types of edema and diseases of the venous circulatory system and to a process for manufacturing this medicament. The dry seed extract is processed to the form of pellets which can be coated to obtain sustained release of the agent. In this way satisfying therapeutical blood levels of the triterpene glycosides as agent are achieved. The finished medicament according to the invention can best be provided as hard gelatin capsule or matrix tablet containing the extract pellets.

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

The present invention provides an antibody to human IL-3Rα chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3Rα chain but does not bind to C domain of the human IL-3Rα chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3Rα as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3Rα antibody as an active ingredient.

The invention relates to a nanometer medicinal elution apparatus in microcellular structure for storing and releasing multiple medicines and a preparation method thereof. The multiple medicines in the invention are selected from medicine therapeutic agents, carrier therapeutic genes and bioactive substances, wherein one or two of the medicine therapeutic agents is / are taxol and / or probucol. The preparation method of the medicinal elution apparatus in the invention mainly comprises the followings: 1) nanometer holes are prepared on the surface of the apparatus body; 2) multiple medicines are coated in the nanometer holes and on the surface of the apparatus body. The apparatus body in the invention does not contain polymers, thereby reducing the risk of long-term thrombus possibly caused by polymers; the nanometer holes on the surface of the apparatus body do not have any influence for mechanical property of the body, thereby being capable of efficiently controlling the releasing rate of medicines and obviously reducing the restenosis rate after surgical operations. The invention can be applied to various medicinal elution implanting apparatuses, particularly having good effects for curing vascular lesion and preventing blood vessel restenosis in vascular stents.

The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX, utilizing an immortalized human cell line stably expressing viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins; an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.

The present teachings provide devices and methods of engaging, capturing, and retrieving emboli. Specifically, one aspect of the present teachings provide a device comprising a generally cylindrical stent body, and a distal net. The stent body is configured to engage and capture emboli, while the distal net is configured to restrict blood flow, and capture embolic debris. Certain embodiments of the present teachings also provides devices and methods of engaging clots while better assist aspiration. Another aspect of the present teachings provide methods of use thereof to percutaneously removeblood clots with minimum risks.

The present invention refers to a recombinant human blood coagulation factor VIII protein and a composition containing it. The present invention also refers to the use of the protein or composition of the invention for manufacturing a medicine for treating hemophilia A. Additionally, the present invention refers to the method of obtaining a recombinant human blood coagulation factor VIII protein. A further object of the present invention is a recombinant protein obtained by the method described herein, and its use in the preparation of a medicine for the treatment of hemophilia A.

A surgical apparatus for treating a blood clot in a vessel of a patient having an elongated member having an outer wall, a first hole at a distal portion and a second hole spaced proximally from the first hole positioned in a side wall. A first lumen is provided within the elongated member for blood flow through the second hole, through the lumen and exiting the first hole to maintain blood flow during treatment of the blood clot. An energy emitter emits energy to the blood clot or hardenings and a connector connects the energy emitter to an external energy source, wherein blood flows into the second hole positioned proximal of the blood clot and exits the first hole distal of the blood clot during activation of the energy emitter. In some instances when the apparatus is introduced from a retrograde ‘upstream” approach blood may flow through the device in the opposite direction.

The invention relates to the field of traditional Chinese medicine, and discloses a repair traditional Chinese medicine used for treating blood cell infected by flaviviridae. The traditional Chinese medicine is prepared from: by weight, herba tubocapsici anomali 30g-80g, cymbopogon citratus 20g-50g, camellia flower 10g-30g, citrus aurantium flower 10g-30g, bitter gourd 20g-50g, mint 20g-50g, phellodendron amurense 10g-30g, cypress leaf 10g-30g, salix leaf 10g-30g, persimmon leaf 15g-35g, perilla nankinensis 10g-20g, radix sophorae flavescentis 30g-60g, eleusine indica 25g-80g, syzygium aromaticum 10g-30g, lonicera japonica 30g-80g, agastache rugosus 20g-50g, portulaca oleracea 10g-30g, glycyrrhiza 5g-15g, chrysanthemum 10g-35g, and foeniculum vulgare 10g-35g. The traditional Chinese medicine has cure effect of the diseases such as dengue, Zika virus, encephalitis, hepatitis and liver cancer infected by flaviviridae spreading, can treat and repair the blood cell from the source, has prophylaxis and treatment effect on flaviviridae diseases, is without any toxicity and side effects, and can improve the cure rate and cure efficiency of patients.